Croce M V, Fejes M, Riera N, Minoldo D A, Segal-Eiras A
Cancer Immunol Immunother. 1985;20(1):91-5. doi: 10.1007/BF00199780.
A total of 122 sera from acute lymphoblastic leukemia (ALL) patients were analyzed for circulating immune complexes (CIC) by two methods: the 125I-Clq binding assay and the polyethylene glycol precipitation test (PEG). The results were correlated with induction, remission and relapse stages of the disease. Using the first method the levels of CIC in induction were 15.18 +/- 9.15, with 19/29 positive cases (65.50%), P less than 0.001 compared with controls. In the remission phase the levels were 9.02 +/- 5.62, 11/45 (24.49%) nonsignificant P value, and in relapse they were 16.14 +/- 11.17 28/48 (58.33%) P less than 0.001. The PEG precipitation test results were: 0.33 +/- 0.10, 8/22 (36.36%); 0.24 +/- 0.11, 10/48 (20.83%) and 0.28 +/- 0.10, 6/28 (21.42%), respectively. Thus the values of CIC as measured by PEG in the three clinical of phases ALL did not differ significantly from controls. This contrasts with results obtained by the radioiodinated C1q binding assay, where the incidence of positive values was significantly higher in induction and in relapse and lower in the remission phase. These observations were extended in sequential vertical studies performed in a group of patients. These results suggest that raised CIC detected by the 125I-C1q method may reflect a progressive state in ALL and that quantitation of these immune complexes may provide an adequate biochemical marker for prognosis.
采用两种方法对122份急性淋巴细胞白血病（ALL）患者的血清进行循环免疫复合物（CIC）分析：125I-Clq结合试验和聚乙二醇沉淀试验（PEG）。结果与疾病的诱导、缓解和复发阶段相关。使用第一种方法，诱导期CIC水平为15.18±9.15，29例中有19例阳性（65.50%），与对照组相比P<0.001。缓解期水平为9.02±5.62，45例中有11例（24.49%），P值无统计学意义，复发期为16.14±11.17，48例中有28例（58.33%），P<0.001。PEG沉淀试验结果分别为：0.33±0.10，8/22（36.36%）；0.24±0.11，10/48（20.83%）和0.28±0.10，6/28（21.42%）。因此，ALL三个临床阶段中通过PEG测量的CIC值与对照组无显著差异。这与放射性碘化C1q结合试验获得的结果形成对比，在该试验中，诱导期和复发期阳性值的发生率显著更高，缓解期更低。在一组患者中进行的连续纵向研究扩展了这些观察结果。这些结果表明，通过125I-C1q方法检测到的CIC升高可能反映了ALL的进展状态，并且这些免疫复合物的定量可能为预后提供一个合适的生化标志物。
